Bio Assays - Commentary – First Supplement to USP 35-NF 30
Amongst others, the USP published the received comments and responses to General Chapter/Section: <1032> Design and Development of Biological Assays in the Commentary – First Supplement to USP 35-NF 30.
The USP received 13 comments to different parts of this chapter. Comments to the following topics are included:
- Necessary Harmonization with compendial references e.g. European Pharmacopoiea
- Helpful case study examples that illustrate the application
- The need that the assay acheive a specific observable response
- Assessment of similarity using the entire concentration-response curve, including the asymptotes.
- Potency assay for assessment of stability
- Need of documenting the source of assay's cell line
The complete comments can be found at Commentary – First Supplement to USP 35-NF 30.
In this respect you may also want to pay attention to ECA's New Education Course on "Bioassays, and Bioanalytics" from 27-28 March 2012 in Copenhagen, Denmark.
Author:
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
16.10.2024US FDA Warning Letter: Lab Data Integrity issues
16.10.2024FDA Warning Letter: Component Testing, Validation, and Stability
16.10.2024EDQM publishes New Chapter "Quality of Data" for Comments
16.10.2024USP Chapter <621> Chromatography: Notice of Intent to Revise
15.10.2024Pharmeuropa Text for Comment: HPTLC for Herbal Products
09.10.2024WHO Biowaiver Project Cycle VII (2025) and Results from Cycle VI (2024)